New hope for Hard-to-Treat cancers? early trial of TTX-MC138 begins

NCT ID NCT06260774

Ongoing Disease control Sponsor: TransCode Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new drug called TTX-MC138 in 16 people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and see if the drug can shrink or stabilize tumors. It is an open-label study, meaning everyone knows they are getting the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TTX-MC138
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is a very early, small trial (16 people) testing safety and dosing. The drug may not shrink tumors or could cause side effects. Success is far from guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Show contact details

Locations

MD Anderson Cancer Center

Houston, Texas, 77230, United States
Mary Crowley Cancer Center

Dallas, Texas, 75230, United States
Next Oncology

Fairfax, Virginia, 22031, United States
START Mountain Region

West Valley City, Utah, 84119, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.